Reactogenicidad de la vacuna Sputnik V en los estudiantes de medicina. Universidad de Carabobo

Autores/as

  • Paola Cabrera Universidad Norbert Wiener. Arequipa, Perú
  • Juan Pernalete-Maldonado Universidad Nacional Experimental de la Fuerza Armada Nacional Bolivariana de Venezuela
  • Yuraima Garcia-Calcurian Escuela de Enfermería “Dra. Gladys Román de Cisneros”, Universidad de Carabobo, Venezuela
  • José Rivas-Naar Coordinación Regional de Docencia, Investigación y Extensión. Corporación de Salud – Aragua. Venezuela
  • Luis Alejos-Aguero Coordinación de Docencia, Investigación y Extensión. Servicio Autónomo Docente Hospital Central de Maracay –Venezuela
  • Elena Duque Medical English North American. University Texas
  • Miriam Barrios Medical English North American. University Texas
  • Mildred Lupi Medical English North American. University Texas

DOI:

https://doi.org/10.35839/repis.6.3.1428

Palabras clave:

epidemiologia, efectos adversos, vacuna Sputnik

Resumen

Objective. To evaluate the reactogenicity of the SPUTNIK V vaccine in post-vaccinated 6th year Medicine students who carry out their care practices in the Autonomous Teaching Service of the Central Hospital of Maracay-Venezuela. Period February 2021- February 2022. Materials and methods. Prospective, evaluative, cross-sectional study. Medicine students were recruited, between 21 and 35 years of age who carried out their internships in the Autonomous Teaching Service of the Central Hospital of Maracay. The most important study variables were: The Sputnik V vaccine and the adverse reactions, evaluated using the anamnesis in an epidemiological consultation after the first 24 hours following the administration of the first dose, and 21 days later, 24 hours after the second dose of the vaccine in the same group. A medical file, validated by three experts, was used. Descriptive statistics, frequency tables and graphs were applied. Results. The predominant age group is between 21-25 years of age, 45 (81.82%) female, 37 (67.27%), 46 (83.67%) from the state of Aragua. The vaccination interval between doses was 3 weeks. The most frequent adverse reactions in the I dose: fever (83.64), malaise (58.18), headache (47.27) and myalgia (43.64%) that decreased significantly in the II dose. (16%) did not show reaction in I and (60%) in I. Conclusion. The post-vaccinated population is young. When receiving the first dose of the vaccine, more adverse reactions appeared than in the second. This is due to activation of the immune system (humoral response against COVID-19).

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Weekly epidemiological update on COVID-19 - 27 April 2022 [Internet]. [citado 18 de julio de 2022]. Disponible en: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19

Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Seguridad y eficacia de una vacuna COVID-19 heteróloga de refuerzo primario basada en vectores rAd26 y rAd5: un análisis intermedio de un ensayo controlado aleatorizado de fase 3 en Rusia. lanceta _ 2022 20 de marzo; 397 (10275):671–681. doi: 10.1016/S0140-6736(21)00234-8.

Córdova E, Bacelar B, Nieto F, Garibaldi F, Aguirre V, Machuca M, et al. SARS-CoV-2 IgG response in symptomatic and asymptomatic COVID-19-infected healthcare workers. Occup Med. 2021;71(4-5): 215-8. doi: 10.1093/occmed/kqab061

Coronavirus disease (COVID-19) – World Health Organization [Internet]. [citado 18 de julio de 2022]. Disponible en: https://www.who.int/emergencies/diseases/novel-coronavirus-2019

Covid-19 Vaccine Tracker: Updated Aug. 26, 2021 - The New York Times. [citado 18 de julio de 2022]. Disponible en: https://www.nytimes.com/interactive/2020/ science/coronavirusvaccinetracker.html#gamaleya

Perrelli, L, Garcia, S, Alfie, V, Klappenbach, R, Vacuna contra el COVID-19. [Internet] 2020. (citado 23 de abril de 2022); Documento de evaluación de tecnologías sanitarias, informe de respuesta rápida N 814. Disponible en: https://docs.bvsalud.org/biblioref/2020/12/1140939/iecs-irr-814-va-1-3.pdf

McCluskey, M, Pozzebon, S, Arias, T, Lister, T. La vacuna rusa Sputnik V amplía su alcance en América Latina [Internet]. CNN. 2021 [citado 18 de julio de 2022]. Disponible en: https://cnnespanol.cnn.com/2021/03/04/la-vacuna-rusa-sputnik-v-amplia-su-alcance-en-america-latina/

Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260-3. doi: 10.1126/science. abb2507

Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020; NEJMoa2028436. doi: 10.1056/NEJMoa2028436

Guerrero-Rodríguez E, Hernán-Gascueña D, Miranda-Serrano MB, Arenas-Jiménez L, Pereira-Feijoo C, Sanjuan-Miguel sanz M. Reactogenicidad e inmunogenicidad tras la inoculación de vacuna frente a SARS-CoV-2 en personal de diálisis. Enferm Nefrol. 2021;24(3):262-70. doi.org/10.37551/s2254-28842021023

Córdova E, Lespada MI, Cecchini D, et al. [Evaluación de la inmunidad humoral inducida por la vacuna sputnik v COVID-19 (gam-COVID-vac) en trabajadores de la salud]. Vacunas. 2022. doi: 10.1016/ j.vacun.2022.01.008

Abbott.Advise Dx SARS-CoV-2 IgGII. [citado 18 de Julio de 2022]. Disponible en: https://www.fda.gov/media/146371/download.

Manual de vigilancia de eventos supuestamente atribuibles a la vacunación o inmunización en la Región de las Américas. [Internet]. [citado 18 de julio de 2022] Disponible en: https://iris.paho.org/handle/10665.2/55384

Curti P, Inglese A, Rancaño C, Saia M, Marcos A. Boletín Epidemiológico Semanal Cuidad Autónoma de Buenos Aires.Argentina.2018;13:18. Disponible en: https://www.buenosaires.gob.ar/sites/gcaba/files/bes_99_se_26_vf.pdf

Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Seguridad y eficacia de una vacuna COVID-19 heteróloga de refuerzo primario basada en vectores rAd26 y rAd5: un análisis intermedio de un ensayo controlado aleatorizado de fase 3 en Rusia. Lanceta. 2022; 397 (10275):671–681. doi: 10.1016/S0140-6736(21)00234-8.

Ojeda DS, González López Ledesma MM, Pallares HM, Costa Navarro GS, Sánchez L, Perazzi B, et al. (2021) Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina. PLoS Pathog 17(1): e1009161. doi: 10.1371/journal.ppat.1009161.

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1

Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet Lond Engl. 2021;397(10277):881-91. doi: 10.1016/S0140-6736(21)00432-3

Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. The Lancet. 2020;395(10240):1845-54. doi: 10.1016/S0140-6736(20)31208-3

Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Lond Engl. 2020;396(10249):479-88. doi: 10.1016/S0140-6736(20)31605-6.

Descargas

Publicado

2022-07-30

Cómo citar

1.
Cabrera P, Pernalete-Maldonado J, Garcia-Calcurian Y, Rivas-Naar J, Alejos-Aguero L, Duque E, Barrios M, Lupi M. Reactogenicidad de la vacuna Sputnik V en los estudiantes de medicina. Universidad de Carabobo. Rev Peru Investig Salud [Internet]. 30 de julio de 2022 [citado 6 de diciembre de 2022];6(3):159-65. Disponible en: https://revistas.unheval.edu.pe/index.php/repis/article/view/1428

Número

Sección

Artículos originales